A Randomized, Multicenter, Phase II Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Trastuzmab (Herceptin) and Docataxel (Taxotere) in Patients with Metastatic HER2-Positive Breast Cancer who have not received prior Chemotherapy for Metastati
|Effective start/end date||12/8/08 → 12/31/13|
- GENENTECH, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.